RESUMO
Zatrephina lineata (Coleoptera: Chrysomelidae) is a phytophagous insect, mainly of plants of the genera Ipomoea and Mikania. The objective was to study the development, survival and to describe the life stages of Z. lineata fed on leaves of Ipomoea pes-caprae. Biological observations were made daily with the aid of a stereoscopic microscope and the instars of this insect identified by the exuvia left between one moulting and the next. The duration of development and survival of the egg, larva and pupa stages and the first, second, third, fourth and fifth instars and of the nymph stage of Z. lineata differed, but not between sexes of this insect. The duration of development of Z. lineata was longer in the larval stage and in the fifth instar, and its survival greater in the egg and pupa stages and in the first and fifth instars. Zatrephina lineata eggs, cream-colored, are ellipsoid and deposited in groups on the adaxial surface of older I. pes-caprae leaves. The larvae of this insect go through five instars, with the first three being gregarious with chemo-behavioral defenses. The exarated pupae of Z. lineata, light yellow in color and with an oval shape flattened dorsoventrally, attach to the abaxial surface of the I. pes-caprae leaves. The shape of adults of this insect is oval, straw yellow in color with lighter longitudinal stripes and females are slightly larger than males.
Assuntos
Besouros , Ipomoea , Larva , Folhas de Planta , Animais , Besouros/classificação , Besouros/crescimento & desenvolvimento , Masculino , Feminino , Folhas de Planta/parasitologia , Larva/crescimento & desenvolvimento , Ipomoea/parasitologia , Pupa/crescimento & desenvolvimento , Estágios do Ciclo de Vida/fisiologiaRESUMO
Intravitreal administration has been widely used since 20 years and has been shown to improve the treatment of diseases of the posterior segment of the eye with infectious origin or in edematous maculopathies. This route of administration allows to achieve high concentration of drug in the vitreous and avoids the problems resulting from systemic administration. However, two basic problems limit the use of intravitreal therapy. Many drugs are rapidly cleared from the vitreous humor; therefore, to reach and to maintain effective therapy repeated injections are necessary. Repeated intravitreal injections increase the risk of endophthalmitis, damage to lens, retinal detachment. Moreover, some drugs provoke a local toxicity at their effective dose inducing side-effects and possible retinal lesions. In this context, the development and the use of new drug delivery systems for intravitreal administration are necessary to treat chronic ocular diseases. Among them, particulate systems such as liposomes have been widely studied. Liposomes are easily injectable and permit to reduce the toxicity and to increase the residence time of several drugs in the eye. They are also able to protect in vivo poorly-stable molecules from degradation such as peptides and nucleic acids. Some promising results have been obtained for the treatment of retinitis induced by cytomegalovirus in human and more recently for the treatment of uveitis in animal. Finally, the fate of liposomes in ocular tissues and fluids after their injection into the vitreous and their elimination routes begin to be more known.
Assuntos
Portadores de Fármacos , Oftalmopatias/tratamento farmacológico , Lipossomos , Preparações Farmacêuticas/administração & dosagem , Corpo Vítreo/fisiologia , Portadores de Fármacos/farmacocinética , Sistemas de Liberação de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Olho/metabolismo , Humanos , Injeções Intravítreas , Lipossomos/farmacocinéticaRESUMO
OBJECTIVES: As of December, 1st, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage. The angiotensin converting enzyme 2 (ACE2) serves as a receptor for SARS-CoV-2. Interaction between ACE2 and SARS-CoV2 spike protein seems to alter the function of ACE2, a key player in the renin-angiotensin system (RAS). The clinical picture of COVID-19 includes acute respiratory distress syndrome (ARDS), cardiomyopathy, multiorgan dysfunction and shock, all of which might result from an imbalance of the RAS. We propose that RAS balance could be restored in COVID-19 patients through MasR activation downstream of ACE2 activity, with 20-hydroxyecdysone (BIO101) a non-peptidic Mas receptor (MasR) activator. Indeed, MasR activation by 20-hydroxyecdysone harbours anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. BIO101, a 97% pharmaceutical grade 20-hydroxyecdysone could then offer a new therapeutic option by improving the respiratory function and ultimately promoting survival in COVID-19 patients that develop severe forms of this devastating disease. Therefore, the objective of this COVA study is to evaluate the safety and efficacy of BIO101, whose active principle is 20-hydroxyecdysone, in COVID-19 patients with severe pneumonia. TRIAL DESIGN: Randomized, double-blind, placebo-controlled, multi-centre, group sequential and adaptive which will be conducted in 2 parts. Part 1: Ascertain the safety and tolerability of BIO101 and obtain preliminary indication of the activity of BIO101, in preventing respiratory deterioration in the target population Part 2: Re-assessment of the sample size needed for the confirmatory part 2 and confirmation of the effect of BIO101 observed in part 1 in the target population. The study is designed as group sequential to allow an efficient run-through, from obtaining an early indication of activity to a final confirmation. And adaptive - to allow accumulation of early data and adapt sample size in part 2 in order to inform the final design of the confirmatory part of the trial. PARTICIPANTS: Inclusion criteria 1. Age: 45 and above 2. A confirmed diagnosis of COVID-19 infection, within the last 14 days, prior to randomization, as determined by PCR or other approved commercial or public health assay, in a specimen as specified by the test used. 3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection symptoms with anticipated hospitalization duration ≥3 days 4. With evidence of pneumonia based on all of the following: a. Clinical findings on a physical examination b. Respiratory symptoms developed within the past 7 days 5. With evidence of respiratory decompensation that started not more than 4 days before start of study medication and present at screening, meeting one of the following criteria, as assessed by healthcare staff: a. Tachypnea: ≥25 breaths per minute b. Arterial oxygen saturation ≤92% c. A special note should be made if there is suspicion of COVID-19-related myocarditis or pericarditis, as the presence of these is a stratification criterion 6. Without a significant deterioration in liver function tests: a. ALT and AST ≤ 5x upper limit of normal (ULN) b. Gamma-glutamyl transferase (GGT) ≤ 5x ULN c. Total bilirubin ≤ 5×ULN 7. Willing to participate and able to sign an informed consent form (ICF). Or, when relevant, a legally authorized representative (LAR) might sign the ICF on behalf of the study participant 8. Female participants should be: at least 5 years post-menopausal (i.e., persistent amenorrhea 5 years in the absence of an alternative medical cause) or surgically sterile; OR a. Have a negative urine pregnancy test at screening b. Be willing to use a contraceptive method as outlined in inclusion criterion 9 from screening to 30 days after last dose. 9. Male participants who are sexually active with a female partner must agree to the use of an effective method of birth control throughout the study and until 3 months after the last administration of the investigational product. (Note: medically acceptable methods of contraception that may be used by the participant and/or partner include combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, etonogestrel implant, each supplemented with a condom, as well as sterilization and vasectomy). 10. Female participants who are lactating must agree not to breastfeed during the study and up to 14 days after the intervention. 11. Male participants must agree not to donate sperm for the purpose of reproduction throughout the study and until 3 months after the last administration of the investigational product. 12. For France only: Being affiliated with a European Social Security. Exclusion criteria 1. Not needing or not willing to remain in a healthcare facility during the study 2. Moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-COVID-19 related conditions 3. Participant on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ECMO), or high-flow Oxygen (delivery of oxygen at a flow of ≥16 L/min.). 4. Participant is not able to take medications by mouth (as capsules or as a powder, mixed in water). 5. Disallowed concomitant medication: Consumption of any herbal products containing 20-hydroxyecdysone and derived from Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g. performance enhancing agents). 6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101. 7. Renal disease requiring dialysis, or known renal insufficiency (eGFR≤30 mL/min/1.73 m2, based on Cockcroft & Gault formula). 8. In France only: a. Non-affiliation to compulsory French social security scheme (beneficiary or right-holder). b. Being under tutelage or legal guardianship. Participants will be recruited from approximately 30 clinical centres in Belgium, France, the UK, USA and Brazil. Maximum patients' participation in the study will last 28 days. Follow-up of participants discharged from hospital will be performed through post-intervention phone calls at 14 (± 2) and 60 (± 4) days. INTERVENTION AND COMPARATOR: Two treatment arms will be tested in this study: interventional arm 350 mg b.i.d. of BIO101 (AP 20-hydroxyecdysone) and placebo comparator arm 350 mg b.i.d of placebo. Administration of daily dose is the same throughout the whole treatment period. Participants will receive the study medication while hospitalized for up to 28 days or until a clinical endpoint is reached (i.e., 'negative' or 'positive' event). Participants who are officially discharged from hospital care will no longer receive study medication. MAIN OUTCOMES: Primary study endpoint: The proportion of participants with 'negative' events up to 28 days. 'Negative' events are defined as respiratory deterioration and all-cause mortality. For the purpose of this study, respiratory deterioration will be defined as any of the following: Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage). Requiring extracorporeal membrane oxygenation (ECMO). Requiring high-flow oxygen defined as delivery of oxygen at a flow of ≥16 L/min. Only if the primary endpoint is significant at the primary final analysis the following Key secondary endpoints will be tested in that order: Proportion of participants with events of respiratory failure at Day 28 Proportion of participants with 'positive' events at Day 28. Proportion of participants with events of all-cause mortality at Day 28 A 'positive' event is defined as the official discharge from hospital care by the department due to improvement in participant condition. Secondary and exploratory endpoints: In addition, a variety of functional measures and biomarkers (including the SpO2 / FiO2 ratio, viral load and markers related to inflammation, muscles, tissue and the RAS / MAS pathways) will also be collected. RANDOMIZATION: Randomization is performed using an IBM clinical development IWRS system during the baseline visit. Block-permuted randomization will be used to assign eligible participants in a 1:1 ratio. In part 1, randomization will be stratified by RAS pathway modulator use (yes/no) and co-morbidities (none vs. 1 and above). In Part 2, randomization will be stratified by centre, gender, RAS pathway modulator use (yes/no), co-morbidities (none vs. 1 and above), receiving Continuous Positive Airway Pressure/Bi-level Positive Airway Pressure (CPAP/BiPAP) at study entry (Yes/No) and suspicion of COVID-19 related myocarditis or pericarditis (present or not). BLINDING (MASKING): Participants, caregivers, and the study team assessing the outcomes are blinded to group assignment. All therapeutic units (TU), BIO101 b.i.d. or placebo b.i.d., cannot be distinguished in compliance with the double-blind process. An independent data-monitoring committee (DMC) will conduct 2 interim analyses. A first one based on the data from part 1 and a second from the data from parts 1 and 2. The first will inform about BIO101 safety, to allow the start of recruitment into part 2 followed by an analysis of the efficacydata, to obtain an indication of activity. The second interim analysis will inform about the sample size that will be required for part 2, in order to achieve adequate statistical power. Numbers to be randomised (sample size) Number of participants randomized: up to 465, in total Part 1: 50 (to obtain the proof of concept in COVID-19 patients). Part 2: 310, potentially increased by 50% (up to 465, based on interim analysis 2) (to confirm the effects of BIO101 observed in part 1). TRIAL STATUS: The current protocol Version is V 10.0, dated on 24.09.2020. The recruitment that started on September 1st 2020 is ongoing and is anticipated to finish for the whole study by March2021. TRIAL REGISTRATION: The trial was registered before trial start in trial registries: EudraCT , No. 2020-001498-63, registered May 18, 2020; and Clinicaltrials.gov, identifier NCT04472728 , registered July 15, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Assuntos
Tratamento Farmacológico da COVID-19 , Ecdisterona/uso terapêutico , Insuficiência Respiratória/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Enzima de Conversão de Angiotensina 2/metabolismo , COVID-19/fisiopatologia , Progressão da Doença , Método Duplo-Cego , Oxigenação por Membrana Extracorpórea/estatística & dados numéricos , Hospitalização , Humanos , Hipóxia/fisiopatologia , Pessoa de Meia-Idade , Mortalidade , Oxigenoterapia/estatística & dados numéricos , Proto-Oncogene Mas , Proteínas Proto-Oncogênicas/metabolismo , Ensaios Clínicos Controlados Aleatórios como Assunto , Receptores de Coronavírus/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Sistema Renina-Angiotensina , Respiração Artificial/estatística & dados numéricos , Insuficiência Respiratória/fisiopatologia , SARS-CoV-2 , Glicoproteína da Espícula de Coronavírus/metabolismo , Taquipneia/fisiopatologia , Resultado do TratamentoRESUMO
PURPOSE: To analyze the influence of age on retinochoroidal wound healing processes and on glial growth factor and cytokine mRNA expression profiles observed after argon laser photocoagulation. METHODS: A cellular and morphometric study was performed that used 44 C57Bl/6J mice: 4-week-old mice (group I, n=8), 6-week-old mice (group II, n=8), 10-12-week-old mice (group III, n=14), and 1-year-old mice (group IV, n=14). All mice in these groups underwent a standard argon laser photocoagulation (50 microm, 400 mW, 0.05 s). Two separated lesions were created in each retina using a slit lamp delivery system. At 1, 3, 7, 14, 60 days, and 4 months after photocoagulation, mice from each of the four groups were sacrificed by carbon dioxide inhalation. Groups III and IV were also studied at 6, 7, and 8 months after photocoagulation. At each time point the enucleated eyes were either mounted in Tissue Tek (OCT), snap frozen and processed for immunohistochemistry or either flat mounted (left eyes of groups III and IV). To determine, by RT-PCR, the time course of glial fibrillary acidic protein (GFAP), vascular endothelial growth factor (VEGF), and monocyte chemotactic protein-1 (MCP-1) gene expression, we delivered ten laser burns (50 microm, 400 mW, 0.05 s) to each retina in 10-12-week-old mice (group III', n=10) and 1-year-old mice (group IV', n=10). Animals from Groups III' and IV' had the same age than those from Groups III and IV, but they received ten laser impacts in each eye and served for the molecular analysis. Mice from Groups III and IV received only two laser impacts per eye and served for the cellular and morphologic study. Retinal and choroidal tissues from these treated mice were collected at 16 h, and 1, 2, 3, and 7 days after photocoagulation. Two mice of each group did not receive photocoagulation and were used as controls. RESULTS: In the cellular and morphologic study, the resultant retinal pigment epithelium interruption expanse was significantly different between the four groups. It was more concise and smaller in the oldest group IV (112.1 microm+/-11.4 versus 219.1 microm+/-12.2 in group III) p<0.0001 between groups III and IV. By contrast, while choroidal neovascularization (CNV) was mild and not readily identifiable in group I, at all time points studied, CNV was more prominent in the (1-year-old mice) Group IV than in the other groups. For instance, up to 14 days after photocoagulation, CNV reaction was statistically larger in group IV than in group III ((p=0.0049 between groups III and IV on slide sections and p<0.0001 between the same groups on flat mounts). Moreover, four months after photocoagulation, the CNV area (on slide sections) was 1,282 microm(2)+/-90 for group III and 2,999 microm(2)+/-115 for group IV (p<0.0001 between groups III and IV). Accordingly, GFAP, VEGF, and MCP-1 mRNA expression profiles, determined by RT-PCR at 16 h, 1, 2, 3, and 7 days postphotocoagulation, were modified with aging. In 1-year-old mice (group IV), GFAP mRNA expression was already significantly higher than in the younger (10-12 week) group III before photocoagulation. After laser burns, GFAP mRNA expression peaked at 16-24 h and on day 7, decreasing thereafter. VEGF mRNA expression was markedly increased after photocoagulation in old mice eyes, reaching 2.7 times its basal level at day 3, while it was only slightly increased in young mice (1.3 times its level in untreated young mice 3 days postphotocoagulation). At all time points after photocoagulation, MCP-1 mRNA expression was elevated in old mice, reaching high levels of expression at 16 h and day 3 respectively. CONCLUSIONS: Our results were based on the study of four different age groups and included not only data from morphological observations but also from a molecular analysis of the various alterations of cytokine signaling and expression. One-year-old mice demonstrated more extensive CNV formation and a slower pace of regression after laser photocoagulation than younger mice. These were accompanied by differences in growth factors and cytokine expression profiles indicate that aging is a factor that aggravates CNV. The above results may provide some insight into possible therapeutic strategies in the future.
Assuntos
Envelhecimento/patologia , Argônio , Corioide/patologia , Fotocoagulação a Laser , Retina/patologia , Retina/cirurgia , Cicatrização , Animais , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Corioide/irrigação sanguínea , Neovascularização de Coroide/patologia , Neovascularização de Coroide/cirurgia , Regulação da Expressão Gênica , Proteína Glial Fibrilar Ácida/genética , Proteína Glial Fibrilar Ácida/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Retina/metabolismo , Epitélio Pigmentado da Retina/patologia , Epitélio Pigmentado da Retina/cirurgia , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
The use of liposomes as carriers for the delivery of biologically active molecules into the eye is of major interest. Indeed, encapsulation of biologically active molecules in liposomes may increase their bioavailability and may induce a sustained release, thus avoiding repeated intraocular injections and reducing side effects. We describe here the fate of rhodamine-conjugated liposomes (Rh-Lip) injected into the vitreous of normal Lewis rats. Twenty-four hours after intravitreal injection fluorescent liposomes were detected in the vitreous, the inner layer of the retina and to a lesser extent in the anterior segment of the eye. In addition, numerous Rh-Lip were also observed in the episclera and conjunctival stroma, in conjunctival lymphatic vessels and cervical lymph nodes (LN) draining the conjunctiva and the eye. In the LN, Rh-Lip were taken up by resident macrophages adjacent to CD4+ and CD8+ T cells. Thus, intravitreal injection of anti-inflammatory drugs loaded in liposomes could modulate the ocular immune microenvironment. In addition the passage of drugs into the cervical LN could alter the immune status of these LN and contribute to the regulation of intraocular inflammation. Our results suggest that this phenomenon should be taken into account to design new therapies based on intraocular drug administration.
Assuntos
Túnica Conjuntiva/metabolismo , Corantes Fluorescentes/metabolismo , Linfonodos/metabolismo , Sistema Linfático/fisiologia , Rodaminas/metabolismo , Corpo Vítreo/metabolismo , Animais , Imuno-Histoquímica , Injeções , Lipossomos , Masculino , Microscopia Confocal , Pescoço , Ratos , Ratos Endogâmicos Lew , Retina/metabolismoRESUMO
PURPOSE: Local delivery of therapeutic molecules encapsulated within liposomes is a promising method to treat ocular inflammation. The purpose of the present study was to define the biodistribution of rhodamine-conjugated liposomes loaded with vasoactive intestinal peptide (VIP), an immunosuppressive neuropeptide, following their intravitreal (IVT) injection in normal rats. METHODS: Healthy seven- to eight-week-old Lewis male rats were injected into the vitreous with empty rhodamine-conjugated liposomes (Rh-Lip) or with VIP-loaded Rh-Lip (VIP-Rh-Lip; 50 mM of lipids with an encapsulation efficiency of 3.0+/-0.4 mmol VIP/mol lipids). Twenty-four h after IVT injection, the eyes, the cervical, mesenteric, and inguinal lymph nodes (LN), and spleen were collected. The phenotype and distribution of cells internalizing Rh-Lip and VIP-Rh-Lip were studied. Determination of VIP expression in ocular tissues and lymphoid organs and interactions with T cells in cervical LN was performed on whole mounted tissues and frozen tissue sections by immunofluorescence and confocal microscopy. RESULTS: In the eye, 24 h following IVT injection, fluorescent liposomes (Rh-Lip and VIP-Rh-Lip) were detected mainly in the posterior segment of the eye (vitreous, inner layer of the retina) and to a lesser extent at the level of the iris root and ciliary body. Liposomes were internalized by activated retinal Müller glial cells, ocular tissue resident macrophages, and rare infiltrating activated macrophages. In addition, fluorescent liposomes were found in the episclera and conjunctiva where free VIP expression was also detected. In lymphoid organs, Rh-Lip and VIP-Rh-Lip were distributed almost exclusively in the cervical lymph nodes (LN) with only a few Rh-Lip-positive cells detected in the spleen and mesenteric LN and none in the inguinal LN. In the cervical LN, Rh-Lip were internalized by resident ED3-positive macrophages adjacent to CD4 and CD8-positive T lymphocytes. Some of these T lymphocytes in close contact with macrophages containing VIP-Rh-Lip expressed VIP. CONCLUSIONS: Liposomes are specifically internalized by retinal Müller glial cells and resident macrophages in the eye. A limited passage of fluorescent liposomes from the vitreous to the spleen via the conventional outflow pathway and the venous circulation was detected. The majority of fluorescent liposomes deposited in the conjunctiva following IVT injection reached the subcapsular sinus of the cervical LN via conjuntival lymphatics. In the cervical LN, Rh-Lip were internalized by resident subcapsular sinus macrophages adjacent to T lymphocytes. Detection of VIP in both macrophages and T cells in cervical LN suggests that IVT injection of VIP-Rh-Lip may increase ocular immune privilege by modulating the loco-regional immune environment. In conclusion, our observations suggest that IVT injection of VIP-loaded liposomes is a promising therapeutic strategy to dampen ocular inflammation by modulating macrophage and T cell activation mainly in the loco-regional immune system.
Assuntos
Rodaminas/administração & dosagem , Rodaminas/farmacocinética , Peptídeo Intestinal Vasoativo/administração & dosagem , Peptídeo Intestinal Vasoativo/farmacocinética , Corpo Vítreo/metabolismo , Animais , Corpo Ciliar/citologia , Corpo Ciliar/efeitos dos fármacos , Corpo Ciliar/metabolismo , Túnica Conjuntiva/citologia , Túnica Conjuntiva/efeitos dos fármacos , Túnica Conjuntiva/metabolismo , Endocitose/efeitos dos fármacos , Injeções , Iris/citologia , Iris/efeitos dos fármacos , Iris/metabolismo , Lipossomos , Linfonodos/citologia , Linfonodos/efeitos dos fármacos , Linfonodos/metabolismo , Tecido Linfoide/citologia , Tecido Linfoide/efeitos dos fármacos , Tecido Linfoide/metabolismo , Masculino , Fagócitos/efeitos dos fármacos , Fagócitos/metabolismo , Fenótipo , Ratos , Ratos Endogâmicos Lew , Rodaminas/farmacologia , Distribuição Tecidual/efeitos dos fármacos , Peptídeo Intestinal Vasoativo/farmacologia , Corpo Vítreo/citologia , Corpo Vítreo/efeitos dos fármacosRESUMO
Brain infection by the laboratory strain challenge virus standard (CVS), a highly neurotropic strain of rabies virus, causes splenocytes to become less responsive to in vitro stimulation with ConA. CVS-induced immune unresponsiveness is less severe in mice lacking the p55 Kd TNF-alpha receptor (p55TNFR(-/-)) than in C57BL/6 mice, despite a similar invasion of the brain. Comparison of CVS infection in these two strains of mice indicated that decreased immune responsiveness is associated with: (1) an in vivo reduction of the percentages of Th1 (IL-2, IFN-gamma and TNF-alpha) but not of Th2 (IL-4) cytokine-secreting T cells; and (2) an in vivo increase of the percentages of CD25 and CD69-expressing splenocytes. In contrast, CVS-induced immune unresponsiveness is not associated with abnormal percentage of T, B, NK cells or monocytes in vivo. The reductions of the CD4/CD8 ratio and of splenocyte expression of I-A(b) during CVS infection are similar in p55TNFR(-/-) and C57BL/6 mice indicating that these two parameters are not linked to the decreased responsiveness of splenocytes. These data suggest that CVS-induced immune unresponsiveness is under the control of the p55 Kd TNF-alpha receptor. We propose that T cell activation through this receptor, in an environment of poor antigen presentation, results in a state of T cells characterized by the reduced production of IL-2, TNF-alpha and IFN-gamma in vivo, the decreased responsiveness of splenocytes to ConA stimulation in vitro and the expression of the activation markers CD25 and CD69.
Assuntos
Encefalite Viral/imunologia , Vírus da Raiva/imunologia , Raiva/imunologia , Receptores do Fator de Necrose Tumoral/imunologia , Fator de Necrose Tumoral alfa/imunologia , Doença Aguda , Animais , Antígenos CD/análise , Antígenos CD/imunologia , Antígenos de Diferenciação de Linfócitos T/análise , Antígenos de Diferenciação de Linfócitos T/imunologia , Complexo CD3/análise , Complexo CD3/imunologia , Relação CD4-CD8 , Concanavalina A/farmacologia , Feminino , Imunofenotipagem , Interferon gama/análise , Interferon gama/imunologia , Interleucina-10/análise , Interleucina-10/imunologia , Interleucina-2/análise , Interleucina-2/imunologia , Interleucina-4/análise , Interleucina-4/imunologia , Interleucina-6/análise , Interleucina-6/imunologia , Lectinas Tipo C , Ativação Linfocitária/efeitos dos fármacos , Ativação Linfocitária/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Receptores de Interleucina-2/análise , Receptores de Interleucina-2/imunologia , Baço/citologia , Baço/imunologia , Baço/virologia , Células Th1/química , Células Th1/imunologia , Células Th1/virologia , Células Th2/química , Células Th2/imunologia , Células Th2/virologia , Fator de Necrose Tumoral alfa/análiseRESUMO
This study was based on the analysis of the relationship established between nursing auxiliaries and their clientele in two Basic Health Units at the time of clients' reception. The theoretical framework used was that of the "help model", whose elements are: attending, responding, personalizing, giving directions, becoming involved, exploring, understanding and acting. Four typical cases are presented, which show that the relationships are not always personalized, the client and the auxiliary do not become involved in the relationship and that there is more concern about the development of technical abilities than about reception. There are different communication attitudes at the same unit. The reception process must be incorporated to the health unit procedures at the same time it must transcend the routine character of daily activities.
Assuntos
Serviços de Saúde/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Admissão do Paciente , Brasil , Humanos , Relações Enfermeiro-PacienteRESUMO
OBJECTIVE: To describe the results of implementing a pilot screening program, in the Castilla y León, for colorectal cancer (CRC) with the faecal occult blood test (iFOBT) using a quantitative immunological latex agglutination assay. METHODS: The study population included 4930 persons between 50-69 years from the Basic Health Area of Medina del Campo. Colonoscopy was performed on those who had a positive iFOBT. The rates of participation were calculated, positivity, acceptance of colonoscopy, detection of lesions, percentages and predictive positive value (PPV) of the test. RESULTS: A total of 2241 (46.33%) people took part. There were 138 (6.15%) positive iFOBT. The rate acceptance of the colonoscopy was 99.27%. CRC was detected in 12 patients (91.66% in early stages), a high risk adenoma (HRA) in 42, and a low risk adenoma (LRA) in 34. The rates of detection were for CRCwas 5.35, 18.74 for HRA, 15.17 for LRA, and 39.26 for all kinds of adenoma. The PPV was 8.69% for CCR, 30.43% for HRA and 24.63% for LRA. CONCLUSIONS: The CRC screening program is feasible in our context. The iFOBT indicators are superior to those of other studies performed using the classic test. The high rates of detection of CRC, and all kinds of adenoma would be enough to justify the study. These together with the diagnosis of CRC in the early stages could lead to a reduction of the mortality.
Assuntos
Adenoma/diagnóstico , Neoplasias Colorretais/diagnóstico , Detecção Precoce de Câncer , Adenoma/epidemiologia , Adenoma/imunologia , Idoso , Área Programática de Saúde , Colonoscopia , Neoplasias Colorretais/epidemiologia , Neoplasias Colorretais/imunologia , Feminino , Humanos , Testes de Fixação do Látex , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Prevalência , Espanha/epidemiologia , Saúde da População UrbanaRESUMO
We investigated the role played by inflammation in acute encephalitis following infection with a neurotropic virus by comparing the disease caused by the CVS strain of rabies virus in C57BL/6 and mice deficient for the p55 Kd TNF-alpha receptor (p55TNFR-/-). Morbidity (weight loss and paralysis) and mortality of infected mice were associated with viral propagation, cytokine (IL-6, IL-10, TNF-alpha and IFN-gamma) production, induction of apoptosis and infiltration of inflammatory cells. Mortality occurred later in p55TNFR-/- (than in C57BL/6 mice. In contrast, morbidity and the number of cells undergoing apoptosis were similar in C57BL/6 and p55TNFR-/- mice.) This suggests that morbidity and mortality are independently regulated and that the death of the animal was not due to CNS apoptosis. Delayed mortality correlated with: a reduction in viral load on day 9 p.i., an increase in IFN-gamma and IL-10 concentrations and a reduction in inflammatory cell infiltration in the CNS. Thus, these data indicate that CVS infection elicits an inflammatory response within the CNS and suggest that cytokines signaling via the p55 Kd TNF-alpha receptor is deleterious for the survival of the host. These results strongly suggest that, the modulation of TNF-alpha and upregulation of IFN-gamma would be a powerful anti-virus strategy in cases of viral encephalitis.
Assuntos
Vírus da Raiva/fisiologia , Raiva/fisiopatologia , Receptores do Fator de Necrose Tumoral/deficiência , Fator de Necrose Tumoral alfa/fisiologia , Animais , Antígenos CD/genética , Antígenos CD/fisiologia , Apoptose , Encéfalo/imunologia , Encéfalo/patologia , Encéfalo/virologia , Citocinas/sangue , Encefalite Viral/fisiopatologia , Encefalite Viral/virologia , Proteína Ligante Fas , Feminino , Interferon gama/fisiologia , Glicoproteínas de Membrana/deficiência , Glicoproteínas de Membrana/fisiologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Mutantes , Paralisia/etiologia , Raiva/complicações , Receptores do Fator de Necrose Tumoral/genética , Receptores do Fator de Necrose Tumoral/fisiologia , Receptores Tipo I de Fatores de Necrose Tumoral , Medula Espinal/imunologia , Medula Espinal/patologia , Medula Espinal/virologia , Replicação Viral , Redução de PesoRESUMO
Following brain infection, the Challenge Virus Standard strain of rabies virus infects the retina. Rabies virus ocular infection induces the infiltration of neutrophils and predominantly T cells into the eye. The role of tumor necrosis factor alpha (TNF-alpha)-lymphotoxin signaling in the control of rabies virus ocular infection and inflammatory cell infiltration was assessed using mice lacking the p55 TNF-alpha receptor (p55TNFR(-/-) mice). The incidence of ocular disease and the intensity of retinal infection were greater in p55TNFR(-/-) mice than in C57BL/6 mice: the aggravation correlated with less neutrophil and T-cell infiltration. This indicates that cellular infiltration is under the control of the p55 TNF-alpha receptor and suggests that inflammatory cells may protect the eye against rabies virus ocular infection. The role of T cells following rabies virus ocular disease was assessed by comparison of rabies virus infection in nude mice with their normal counterparts. Indeed, the incidence and severity of the rabies virus ocular disease were higher in athymic nude mice than in BALB/c mice, indicating that T lymphocytes are protective during rabies virus ocular infection. Moreover, few T cells and neutrophils underwent apoptosis in rabies virus-infected retina. Altogether, these data suggest that T lymphocytes and neutrophils are able to enter the eye, escape the immune privilege status, and limit rabies virus ocular disease. In conclusion, rabies virus-mediated eye disease provides a new model for studying mechanisms regulating immune privilege during viral infection.
Assuntos
Antígenos CD/fisiologia , Infecções Oculares Virais/imunologia , Raiva/imunologia , Receptores do Fator de Necrose Tumoral/fisiologia , Linfócitos T/imunologia , Animais , Apoptose , Complexo CD3/análise , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Nus , Receptores Tipo I de Fatores de Necrose TumoralRESUMO
A retroviral element (MSRV) defining a family of genetically inherited endogenous retroviruses (HERV-W) has recently been characterized in cell cultures from patients with multiple sclerosis (MS). To address the possible relationship with MS, direct detection of circulating virion RNA was proposed but revealed technically difficult to perform in standardized conditions, in the face of multiple endogenous HERV-W copies. A parallel approach has evaluated MSRV potential pathogenicity in relation to characteristic features of multiple sclerosis, in particular, T-lymphocyte-mediated immunopathology. We report here that MSRV particles induce T-lymphocyte response with a bias in the Vbeta16 chain usage in surface receptor, whatever the HLA DR of the donor. A recombinant MSRV envelope-but not core-protein reproduced similar nonconventional activation. Molecular analysis of Vbeta CDR3 showed that Vbeta16 expansions are polyclonal. Our results thus provide evidence that MSRV envelope protein can trigger an abnormal immune response with similar characteristics to that of superantigens.
Assuntos
Retrovirus Endógenos/imunologia , Ativação Linfocitária/imunologia , Esclerose Múltipla/virologia , Infecções por Retroviridae/imunologia , Linfócitos T/imunologia , Proteínas do Envelope Viral/imunologia , Antígenos Virais/imunologia , Células Cultivadas , Citocinas/metabolismo , Retrovirus Endógenos/genética , Humanos , Leucócitos Mononucleares/metabolismo , Leucócitos Mononucleares/virologia , Esclerose Múltipla/imunologia , Receptores de Antígenos de Linfócitos T alfa-beta/metabolismo , Proteínas Recombinantes/imunologia , Infecções por Retroviridae/virologia , Linfócitos T/metabolismo , Células Tumorais Cultivadas , Vírion/imunologiaRESUMO
Objetivo: Describir los resultados de la implantación del programa piloto, en la comunidad de Castilla y León, del cribado de cáncer colorrectal (CCR) mediante la detección de sangre oculta en heces utilizando una prueba inmunológica cuantitativa de aglutinación en látex (TSOHi). Métodos: Población diana de 4.930 personas entre 50-69 anos de la zona básica de salud de Medina del Campo. A los que presentaron TSOHi positivo se les realizó colonoscopia. Se calcularon tasas de participación, positividad, aceptación de colonoscopia, detección de lesiones, porcentajes y valor predictivo positivo (VPP) de la prueba. Resultados: La tasa de participación fue de 2.241 personas (46.33%). Los TSOHi positivos fueron 138 (6,15%). La tasa de aceptación de la colonoscopia fue del 99,27%. Se detectaron 12 pacientes con CCR (el 91,66% en estadios precoces), 42 con adenoma de alto riesgo (AAR) y 34 con adenoma de bajo riesgo (ABR). Las tasas de detección fueron para el CCR de 5,35, para el AAR de 18,74, para el ABR de 15,17 y del 39,26 para todo tipo de adenoma. El VPP fue del 8,69% para el CCR, del 30,43% para el AAR y del 24,63% para el ABR. Conclusiones: El programa de detección de CCR es factible en nuestro contexto. Los indicadores del TSOHi son superiores a los de otros estudios realizados con pruebas clásicas. Las altas tasas de detección de CCR y de todo tipo de adenoma justificarían por sí solas el estudio. Estas, junto con la precocidad del diagnóstico de CCR, harían posible anticipar una reducción de la mortalidad (AU)
Objective: To describe the results of implementing a pilot screening program, in the Castilla y León, for colorectal cancer (CRC) with the faecal occult blood test (iFOBT) using a quantitative immunological latex agglutination assay. Methods: The study population included 4930 persons between 50-69 years from the Basic Health Area of Medina del Campo. Colonoscopy was performed on those who had a positive iFOBT. The rates of participation were calculated, positivity, acceptance of colonoscopy, detection of lesions, percentages and predictive positive value (PPV) of the test. Results: A total of 2241 (46.33%) people took part. There were 138 (6.15%) positive iFOBT. The rate acceptance of the colonoscopy was 99.27%. CRC was detected in 12 patients (91.66% in early stages), a high risk adenoma (HRA) in 42, and a low risk adenoma (LRA) in 34. The rates of detection were for CRCwas 5.35, 18.74 for HRA, 15.17 for LRA, and 39.26 for all kinds of adenoma. The PPV was 8.69% for CCR, 30.43% for HRA and 24.63% for LRA. Conclusions: The CRC screening program is feasible in our context. The iFOBT indicators are superior to those of other studies performed using the classic test. The high rates of detection of CRC, and all kinds of adenoma would be enough to justify the study. These together with the diagnosis of CRC in the early stages could lead to a reduction of the mortality (AU)